JNJ vs ABBV
Diversified pharma. Compare price, valuation, growth, profitability, and balance-sheet quality — all in one view.
Highlighted values indicate the better reading for that metric, where direction is unambiguous. Lower is generally better for valuation multiples and leverage; higher is better for growth, margin, and cash-flow metrics. Educational data only, not investment advice.
Next research paths
Open the full JNJ stock page with chart, fundamentals, FAQ, and news context.
Open the full ABBV stock page with chart, fundamentals, FAQ, and news context.
Check the next earnings date and reporting history for JNJ.
Move from side-by-side comparison into open desk notes and live market context.
JNJ vs ABBV — common questions
Is JNJ or ABBV the better stock?
Across the valuation, growth, and profitability metrics compared on this page, ABBV shows the stronger reading on more of them (6 vs 4). A metric tally is not a recommendation — the right pick depends on your time horizon and risk tolerance.
Which is bigger, JNJ or ABBV?
JNJ has the larger market capitalization — JNJ is about $613.02B versus $447.62B for ABBV.
Which grows faster, JNJ or ABBV?
ABBV shows the faster year-over-year revenue growth — JNJ at 9.9% versus 12.4% for ABBV.
Is JNJ or ABBV cheaper?
On forward price-to-earnings, ABBV trades at the lower multiple — JNJ at 20x versus 15.6x for ABBV.
What is the difference between JNJ and ABBV?
Johnson & Johnson operates in the Healthcare sector, while AbbVie Inc. operates in the Healthcare sector. This page compares the two across price, valuation multiples, growth, margins, and balance-sheet quality.
Go deeper than a side-by-side.
Add JNJ and ABBV to your Meridian watchlist for live alerts, AI-driven setups, and full earnings coverage.